Actively Recruiting
Observational Study of the Updated Model G2-TRIO Inserter for the Travoprost Intracameral Implant in Adults with Open-Angle Glaucoma or Ocular Hypertension
Led by Glaukos Corporation · Updated on 2026-02-27
30
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate the updated inserter Model G2-TRIO used to administer the Travoprost intracameral implant for patients with Open Angle Glaucoma OAG or Ocular Hypertension OH. The study is observational and focuses on the clinical use of this updated device in a real-world setting. Participants will receive the Travoprost intracameral implant, 75 mcg, which is administered using the sterile, single-dose updated inserter Model G2-TRIO. The study observes the use of this new inserter to assess its performance in delivering the implant. During the study, researchers will monitor successful implantation within one day after administration. Participants will be involved in evaluations related to the implant procedure, with safety and success assessed shortly after treatment. The study is expected to continue until July 2026.
CONDITIONS
Brief Title
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
